ß-cell specific overexpression of suppressor of cytokine signalling-3 does not protect against multiple low dose streptozotocin induced type 1 diabetes in mice

TY - JOUR

T1 - ß-cell specific overexpression of suppressor of cytokine signalling-3 does not protect against multiple low dose streptozotocin induced type 1 diabetes in mice

AU - Börjesson, A

AU - Rønn, S G

AU - Karlsen, A E

AU - Billestrup, Nils

AU - Sandler, S

N1 - Copyright © 2011 Elsevier B.V. All rights reserved.

PY - 2011/4/30

Y1 - 2011/4/30

N2 - We investigated the impact of β-cell specific overexpression of suppressor of cytokine signalling-3 (SOCS-3) on the development of multiple low dose streptozotocin (MLDSTZ) induced Type 1 diabetes and the possible mechanisms involved. MLDSTZ treatment was administered to RIP-SOCS-3 transgenic and wild-type (wt) mice and progression of hyperglycemia monitored. Isolated islets from both strains were exposed to human IL-1β (25 U/ml) or a combination of human IL-1β (25 U/ml) and murine IFN-γ (1000. U/ml) for 24 h or 48 h and we investigated the expression of IL-1 receptor antagonist (IL-1Ra) mRNA in islet cells and secretion of IL-1Ra into culture medium. MLDSTZ treatment caused gradual hyperglycemia both in the wt mice and in the transgenic mice with the latter tending to be more sensitive. In vitro experiments on wt and transgenic islets did not reveal any differences in sensitivity to damaging effects of STZ. Exposure of wt islets to IL-1β or IL-1β + IFN-γ seemed to lead to a failing IL-1Ra response from SOCS-3 transgenic islets. It could be that an increased expression of a possible protective molecule against β-cell destruction may lead to a dampered response of another putative protective molecule. This may have counteracted a protective effect against MLDSTZ in SOCS-3 transgenic mice.

AB - We investigated the impact of β-cell specific overexpression of suppressor of cytokine signalling-3 (SOCS-3) on the development of multiple low dose streptozotocin (MLDSTZ) induced Type 1 diabetes and the possible mechanisms involved. MLDSTZ treatment was administered to RIP-SOCS-3 transgenic and wild-type (wt) mice and progression of hyperglycemia monitored. Isolated islets from both strains were exposed to human IL-1β (25 U/ml) or a combination of human IL-1β (25 U/ml) and murine IFN-γ (1000. U/ml) for 24 h or 48 h and we investigated the expression of IL-1 receptor antagonist (IL-1Ra) mRNA in islet cells and secretion of IL-1Ra into culture medium. MLDSTZ treatment caused gradual hyperglycemia both in the wt mice and in the transgenic mice with the latter tending to be more sensitive. In vitro experiments on wt and transgenic islets did not reveal any differences in sensitivity to damaging effects of STZ. Exposure of wt islets to IL-1β or IL-1β + IFN-γ seemed to lead to a failing IL-1Ra response from SOCS-3 transgenic islets. It could be that an increased expression of a possible protective molecule against β-cell destruction may lead to a dampered response of another putative protective molecule. This may have counteracted a protective effect against MLDSTZ in SOCS-3 transgenic mice.

KW - Animals

KW - Cells, Cultured

KW - Diabetes Mellitus, Experimental

KW - Diabetes Mellitus, Type 1

KW - Gene Expression Regulation

KW - Hyperglycemia

KW - Insulin-Secreting Cells

KW - Mice

KW - Mice, Inbred C57BL

KW - Mice, Transgenic

KW - Receptor, Interferon alpha-beta

KW - Streptozocin

KW - Suppressor of Cytokine Signaling Proteins

U2 - 10.1016/j.imlet.2010.12.007

DO - 10.1016/j.imlet.2010.12.007

M3 - Journal article

C2 - 21237203

SN - 0165-2478

VL - 136

SP - 74

EP - 79

JO - Immunology Letters

JF - Immunology Letters

IS - 1

ER -